NOX-A12 (olaptesed pegol) is currently under development as a combination therapy in multiple oncology indications. The company recently reported top-line data from its Phase 1/2 combination trial in metastatic pancreatic and colorectal cancer together with MSD’s KEYTRUDA®.
NOXXON initiated a second combination trial of NOX-A12 with radiotherapy for clinical treatment of brain cancer (glioblastoma/glioma). NOX-A12 has received orphan drug designation for glioblastoma in the United States and glioma in Europe.

Mechanisms of action
NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine (signaling) protein. In cancer, it acts as a communication bridge or sign post between tumor cells and their environment, promoting tumor proliferation, new blood vessel formation and metastasis and reduces tumor apoptosis (cell death) (Source: Guo et al., 2015). NOX-A12 binds to two key sites in chemokine proteins to disrupt their activity and target them for destruction.

NOX-A12 is designed to fight solid tumors by modulating the tumor microenvironment in two distinct ways:

  • Break tumor protection enabling active immune cells, T-cells, to enter the tumor with the aim of unleashing the full potential of immuno-oncology approaches, such as immune checkpoint inhibitors*
  • Block tumor repair: through preventing the attraction of ‘repair cells’ to the tumors obstructing tumor re-growth following radiotherapy

    *Fearon, D. T. (2014). "The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance." Cancer Immunol Res 2(3): 187-193.


Presentation of the final clinical results from the Phase 1/2 study with CXCL12 inhibitor, NOX-A12, and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Presented by: Dr. Niels Halama
Head of Department of Translational Immunotherapy at the German Cancer Research Center (DKFZ), Heidelberg
Medical Oncologist at the National Centre for Tumor Diseases (NCT), Heidelberg

Recent clinical studies available at clinicaltrials.gov

  • Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (GLORIA)
    (ref: NCT04121455)
    Status: recruiting
  • Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (Keynote-559)
    (ref: NCT03168139)
    Status: completed

Recent NOX-A12 press releases

Recent NOX-A12 publications


NOX-A12 press release archive

NOX-A12 publication archive